Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration
Aim: Understanding barriers and facilitators to pharmacogenomics (PGx) implementation and how to structure a clinical program with the Veterans Health Administration (VA). Materials & methods: Healthcare provider (HCP) survey at 20 VA facilities assessing PGx knowledge/acceptance and qualitative interviews to understand how best to design and sustain a national program. Results: 186 (12% response rate) surveyed believed PGx informs drug efficacy (74.7%) and adverse events (71.0%). Low confidence in knowledge (43.0%) and ability to implement (35.4-43.5%). 23 (60.5% response rate) interviewees supported a nationally program to oversee VA education, consultation and IT resources. Prescribing HCPs should be directing local activities. Conclusion: HCPs recognize PGx value but are not prepared to implement. Healthcare systems should build system-wide programs for implementation education and support.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 25(2024), 3 vom: 05. Feb., Seite 133-145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Rebekah Ryanne [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Education |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2023-0193 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369306996 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369306996 | ||
| 003 | DE-627 | ||
| 005 | 20240329000651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0193 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM369306996 | ||
| 035 | |a (NLM)38440834 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Rebekah Ryanne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Understanding barriers and facilitators to pharmacogenomics (PGx) implementation and how to structure a clinical program with the Veterans Health Administration (VA). Materials & methods: Healthcare provider (HCP) survey at 20 VA facilities assessing PGx knowledge/acceptance and qualitative interviews to understand how best to design and sustain a national program. Results: 186 (12% response rate) surveyed believed PGx informs drug efficacy (74.7%) and adverse events (71.0%). Low confidence in knowledge (43.0%) and ability to implement (35.4-43.5%). 23 (60.5% response rate) interviewees supported a nationally program to oversee VA education, consultation and IT resources. Prescribing HCPs should be directing local activities. Conclusion: HCPs recognize PGx value but are not prepared to implement. Healthcare systems should build system-wide programs for implementation education and support | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a education | |
| 650 | 4 | |a healthcare systems | |
| 650 | 4 | |a implementation science | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a quality improvement | |
| 700 | 1 | |a Benevent, Richelle |e verfasserin |4 aut | |
| 700 | 1 | |a Sperber, Nina R |e verfasserin |4 aut | |
| 700 | 1 | |a Bates, Jill S |e verfasserin |4 aut | |
| 700 | 1 | |a Villa, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Weeraratne, Dilhan |e verfasserin |4 aut | |
| 700 | 1 | |a Burrell, Timothy A |e verfasserin |4 aut | |
| 700 | 1 | |a Voora, Deepak |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 25(2024), 3 vom: 05. Feb., Seite 133-145 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:05 |g month:02 |g pages:133-145 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0193 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 3 |b 05 |c 02 |h 133-145 | ||